Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2018-03-31, filed 2018-05-14, with 30 holding rows worth $186,623,000.

Accession
0001140361-18-023316
Filed
2018-05-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2018

A holdings report, 30 entries on the cover page, a total value of $186,623,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $186,623,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOSPECIFICS TECHNOLOGIES090931106COM590,025$26,162,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM5,141,746$20,053,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW5,761,581$17,342,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM984,584$16,590,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM2,577,996$16,151,000thousands by filing date
VIVEVE MED INC92852W204COM NEW3,849,711$14,090,000thousands by filing date
CUMBERLAND PHARMACEUTICALS I230770109COM1,323,041$8,838,000thousands by filing date
BIODELIVERY SCIENCES INTL IN09060J106COM3,706,084$8,339,000thousands by filing date
CARDIOME PHARMA CORP14159U301COM NO PAR3,241,550$7,520,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW1,860,000$6,510,000thousands by filing date
ALIMERA SCIENCES INC016259103COM6,180,033$6,365,000thousands by filing date
DOVA PHARMACEUTICALS INC25985T102COM184,000$4,990,000thousands by filing date
OPHTHOTECH CORP683745103COM1,593,119$4,365,000thousands by filing date
VERACYTE INC COM92337F107Stock773,889$4,303,000thousands by filing date
CONFORMIS INC20717E101COM2,777,711$4,028,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS263,974$3,286,000thousands by filing date
CANCER GENETICS INC.13739u104COM1,772,741$2,925,000thousands by filing date
MEDICREA INTERNATIONALF6112U109COM714,729$2,778,000thousands by filing date
STEADYMED LTDM84920103SHS721,308$2,344,000thousands by filing date
INVUITY INC46187J205COM NEW507,028$1,952,000thousands by filing date
GEMPHIRE THERAPEUTICS INC36870A108COM242,812$1,581,000thousands by filing date
SIERRA ONCOLOGY INC82640U107COM570,987$1,182,000thousands by filing date
INVITAE CORP46185L103COM219,022$1,027,000thousands by filing date
ZOSANO PHARMA CORP98979H202COM NEW200,000$1,008,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS129,756$666,000thousands by filing date
EVOLUS INC30052C107COM59,229$535,000thousands by filing date
IMMUNE DESIGN CORP.45252L103Common Stock161,226$532,000thousands by filing date
SCYNEXIS INC COM NEW811292101Common Stock380,083$509,000thousands by filing date
EYENOVIA INC30234E104COM39,902$365,000thousands by filing date
AQUINOX PHARMACEUTICALS INC03842B101COM20,374$287,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-18-023316this filing2018-05-14acceptance time not in the bulk data set